{"id":35427,"date":"2025-10-22T19:12:23","date_gmt":"2025-10-22T19:12:23","guid":{"rendered":"https:\/\/www.euforea.org\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/"},"modified":"2026-08-20T14:02:53","modified_gmt":"2026-08-20T14:02:53","slug":"essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/","title":{"rendered":"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"35427\" class=\"elementor elementor-35427 elementor-16726\" data-elementor-post-type=\"news\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0406419 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no e-con e-parent\" data-id=\"0406419\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-843a778 elementor-widget elementor-widget-euforea_general_content\" data-id=\"843a778\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"euforea_general_content.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"paragraphs\">\n    <div data-quickedit-entity-id=\"paragraph\/842\" class=\"paragraph paragraph--text-columns paragraph-id--842 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\" data-once=\"quickedit\" data-quickedit-entity-instance-id=\"0\">\n      <div class=\"inner--wide\">\n        <div class=\"text__text text text--paragraph\">\n        \t          <p>La rhinosinusite chronique avec polypes nasaux (CRSwNP) est principalement due \u00e0 une inflammation de type 2 impliquant les voies IL-4\/IL-13, IL-5 et IgE. Des biom\u00e9dicaments tels que le Dupilumab, le Mepolizumab et l\u2019Omalizumab ciblent ces m\u00e9diateurs cl\u00e9s et ont d\u00e9montr\u00e9 une efficacit\u00e9 clinique significative. <\/p>\n<p>Cependant, les preuves comparatives directes \u00e9taient limit\u00e9es \u2014 jusqu\u2019\u00e0 l\u2019<strong>essai EVEREST<\/strong> (EValuating trEatment RESponses of dupilumab versus omalizumab), la premi\u00e8re \u00e9tude internationale, randomis\u00e9e, en double aveugle de phase 4 visant \u00e0 \u00e9valuer les deux biom\u00e9dicaments en face \u00e0 face chez des patients atteints de CRSwNP s\u00e9v\u00e8re et non contr\u00f4l\u00e9e, avec ou sans asthme. Cette vid\u00e9o passe en revue la conception de l\u2019essai, les r\u00e9sultats et les perspectives m\u00e9canistiques, en soulignant les implications pour la th\u00e9rapie de pr\u00e9cision dans la prise en charge de la CRSwNP. <\/p>\n<p>Cliquez <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41033334\/\"><strong>ici<\/strong><\/a> pour lire le plus r\u00e9cent article sur EVEREST dans PubMed.<\/p>\n<p>Regardez cet \u00e9pisode avec nos invit\u00e9s sp\u00e9ciaux, le <strong>Prof. Eugenio De Corso (Italie)<\/strong> et le <strong>Prof. Joaquim Mullol (Espagne)<\/strong>, pour comprendre comment les th\u00e9rapies biologiques transforment les soins pour les patients atteints de polypes nasaux et d\u2019asthme !<\/p>\n        <\/div>\n      <\/div>\n    <\/div>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-05eafb3 e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no e-con e-parent\" data-id=\"05eafb3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d307a7b elementor-widget elementor-widget-video\" data-id=\"d307a7b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;youtube_url&quot;:&quot;https:\\\/\\\/youtu.be\\\/zGmk0o82LYQ&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<div class=\"elementor-video\"><\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>La rhinosinusite chronique avec polypes nasaux (CRSwNP) est principalement due \u00e0 une inflammation de type 2 impliquant les voies IL-4\/IL-13, IL-5 et IgE. Des biom\u00e9dicaments tels que le Dupilumab, le Mepolizumab et l\u2019Omalizumab ciblent ces m\u00e9diateurs cl\u00e9s et ont d\u00e9montr\u00e9 une efficacit\u00e9 clinique significative. Cependant, les preuves comparatives directes \u00e9taient limit\u00e9es \u2014 jusqu\u2019\u00e0 l\u2019essai EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), la premi\u00e8re \u00e9tude internationale, randomis\u00e9e, en double aveugle de phase 4 visant \u00e0 \u00e9valuer les deux biom\u00e9dicaments en face \u00e0 face chez des patients atteints de CRSwNP s\u00e9v\u00e8re et non contr\u00f4l\u00e9e, avec ou sans asthme. Cette vid\u00e9o passe en revue la conception de l\u2019essai, les r\u00e9sultats et les perspectives m\u00e9canistiques, en soulignant les implications pour la th\u00e9rapie de pr\u00e9cision dans la prise en charge de la CRSwNP. Cliquez ici pour lire le plus r\u00e9cent article sur EVEREST dans PubMed. Regardez cet \u00e9pisode avec nos invit\u00e9s sp\u00e9ciaux, le Prof. Eugenio De Corso (Italie) et le Prof. Joaquim Mullol (Espagne), pour comprendre comment les th\u00e9rapies biologiques transforment les soins pour les patients atteints de polypes nasaux et d\u2019asthme !<\/p>\n","protected":false},"author":9,"featured_media":35430,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[169],"tags":[],"class_list":["post-35427","news","type-news","status-publish","has-post-thumbnail","hentry","category-emissions-dactualite-euforea"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP\" \/>\n<meta property=\"og:description\" content=\"La rhinosinusite chronique avec polypes nasaux (CRSwNP) est principalement due \u00e0 une inflammation de type 2 impliquant les voies IL-4\/IL-13, IL-5 et IgE. Des biom\u00e9dicaments tels que le Dupilumab, le Mepolizumab et l\u2019Omalizumab ciblent ces m\u00e9diateurs cl\u00e9s et ont d\u00e9montr\u00e9 une efficacit\u00e9 clinique significative. Cependant, les preuves comparatives directes \u00e9taient limit\u00e9es \u2014 jusqu\u2019\u00e0 l\u2019essai EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), la premi\u00e8re \u00e9tude internationale, randomis\u00e9e, en double aveugle de phase 4 visant \u00e0 \u00e9valuer les deux biom\u00e9dicaments en face \u00e0 face chez des patients atteints de CRSwNP s\u00e9v\u00e8re et non contr\u00f4l\u00e9e, avec ou sans asthme. Cette vid\u00e9o passe en revue la conception de l\u2019essai, les r\u00e9sultats et les perspectives m\u00e9canistiques, en soulignant les implications pour la th\u00e9rapie de pr\u00e9cision dans la prise en charge de la CRSwNP. Cliquez ici pour lire le plus r\u00e9cent article sur EVEREST dans PubMed. Regardez cet \u00e9pisode avec nos invit\u00e9s sp\u00e9ciaux, le Prof. Eugenio De Corso (Italie) et le Prof. Joaquim Mullol (Espagne), pour comprendre comment les th\u00e9rapies biologiques transforment les soins pour les patients atteints de polypes nasaux et d\u2019asthme !\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T14:02:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1748\" \/>\n\t<meta property=\"og:image:height\" content=\"1015\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/\",\"name\":\"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EVEREST-Trial-_Teaser.jpg\",\"datePublished\":\"2025-10-22T19:12:23+00:00\",\"dateModified\":\"2026-08-20T14:02:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EVEREST-Trial-_Teaser.jpg\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EVEREST-Trial-_Teaser.jpg\",\"width\":1748,\"height\":1015},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/news\\\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/","og_locale":"fr_FR","og_type":"article","og_title":"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP","og_description":"La rhinosinusite chronique avec polypes nasaux (CRSwNP) est principalement due \u00e0 une inflammation de type 2 impliquant les voies IL-4\/IL-13, IL-5 et IgE. Des biom\u00e9dicaments tels que le Dupilumab, le Mepolizumab et l\u2019Omalizumab ciblent ces m\u00e9diateurs cl\u00e9s et ont d\u00e9montr\u00e9 une efficacit\u00e9 clinique significative. Cependant, les preuves comparatives directes \u00e9taient limit\u00e9es \u2014 jusqu\u2019\u00e0 l\u2019essai EVEREST (EValuating trEatment RESponses of dupilumab versus omalizumab), la premi\u00e8re \u00e9tude internationale, randomis\u00e9e, en double aveugle de phase 4 visant \u00e0 \u00e9valuer les deux biom\u00e9dicaments en face \u00e0 face chez des patients atteints de CRSwNP s\u00e9v\u00e8re et non contr\u00f4l\u00e9e, avec ou sans asthme. Cette vid\u00e9o passe en revue la conception de l\u2019essai, les r\u00e9sultats et les perspectives m\u00e9canistiques, en soulignant les implications pour la th\u00e9rapie de pr\u00e9cision dans la prise en charge de la CRSwNP. Cliquez ici pour lire le plus r\u00e9cent article sur EVEREST dans PubMed. Regardez cet \u00e9pisode avec nos invit\u00e9s sp\u00e9ciaux, le Prof. Eugenio De Corso (Italie) et le Prof. Joaquim Mullol (Espagne), pour comprendre comment les th\u00e9rapies biologiques transforment les soins pour les patients atteints de polypes nasaux et d\u2019asthme !","og_url":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","article_modified_time":"2026-08-20T14:02:53+00:00","og_image":[{"width":1748,"height":1015,"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/","url":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/","name":"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","datePublished":"2025-10-22T19:12:23+00:00","dateModified":"2026-08-20T14:02:53+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EVEREST-Trial-_Teaser.jpg","width":1748,"height":1015},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/fr\/news\/essai-everest-la-premiere-comparaison-directe-de-2-biomedicaments-dans-la-crswnp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"Essai EVEREST : La premi\u00e8re comparaison directe de 2 biom\u00e9dicaments dans la CRSwNP"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=35427"}],"version-history":[{"count":1,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35427\/revisions"}],"predecessor-version":[{"id":35431,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35427\/revisions\/35431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/35430"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=35427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=35427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=35427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}